IFRX News & Events

InflaRx announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions and liver toxicity. These results further support izicopan's potential as a differentiated, oral C5a receptor inhibitor. To build upon previous CYP interaction data for izicopan, which showed only marginal inhibition of CYP3A4 in a time-dependent inhibition IC50 shift assay, InflaRx conducted a mechanistically informative Ki-based TDI study. While TDI shift assays serve as rapid screening tools to identify potential time-dependent inhibition, Ki/Kinact studies provide a more definitive and quantitative assessment, enabling a reliable determination of the presence or absence of time-dependent inhibition. The Ki-based TDI study confirms that izicopan does not inhibit CYP3A4 and exhibits no time-dependent inhibition up to the highest tested concentration, supporting a low risk of clinically relevant DDIs. Using two probe substrates, midazolam and testosterone, no evidence of CYP3A4 time-dependent inhibition was observed, providing mechanistic confirmation of izicopan's favorable pharmacological profile. This feature is particularly important, as time-dependent CYP3A4 inhibition can result in DDIs, hepatotoxicity, or reduced metabolism of concomitant medications such as corticosteroids.

InflaRx announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum were featured in an oral presentation during the late-breaking research abstract session at the 2026 American Academy of Dermatology annual meeting being held March 27-31, 2026, in Denver. The data presented included signals of clinical activity across multiple measures, with higher rates of complete remission, target ulcer closure, and reductions in ulcer volume, as well as a positive safety profile. The primary endpoint, complete target ulcer closure, was achieved by 20.8% of vilobelimab patients versus 16.7% on placebo. Complete disease remission occurred more frequently with vilobelimab than placebo. In addition, over one-third of vilobelimab-treated patients achieved more than a 50% reduction in ulcer volume compared with 16.7% of patients receiving placebo. Physician Global Assessment scores and Dermatology Life Quality Index also showed trends favoring vilobelimab. Vilobelimab treatment also was shown to substantially reduce C5a levels, with mean change from baseline of 76.6% compared to 13.5% with placebo. The treatment was generally well tolerated, with most adverse events reported as mild to moderate and similar rates of serious adverse events between groups.

Reports revenue EUR 29.3M vs. EUR 165.8M last year. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "With the strong Phase 2a results reported in hidradenitis suppurativa and chronic spontaneous urticaria, and its best-in-class potential, we made the strategic decision to focus our resources on izicopan. We are in active discussions with the FDA for the design of our Phase 2b trial in HS and look forward to establishing a clear path forward soon. By tightly focusing the Company on izicopan in select inflammation and immunology indications, we believe we are well positioned to advance to the next stage of development and effectively execute our plans."